Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Cross Asset Strategy

<ul>
<li>Following the £2m fund raise on 4 July 2025 at 0.3p, it’s been a busy two months.</li>
<li>The announcements in August include a paid contract extension with a global partner, an update on licensing opportunities, and a new Biomarker Discovery service launch.</li>
<li>Aptamer is a life science Company developing customised affinity binders through its proprietary Optimer platform which enables clients to take new approaches in therapeutics, diagnostics, and research applications. </li>
</ul>


Following the £2m fund raise on 4 July 2025 at 0.3p, it’s been a busy two months.
The announcements in August include a paid contract extension with a global partner, an update on licensing opportunities, and a new Biomarker Discovery service launch.
Aptamer is a life science Company developing customised affinity binders through its proprietary Optimer platform which enables clients to take new approaches in therapeutics, diagnostics, and research applications. 


Friday Take Away: 29 August 2025